Company intelligence / Profile preview

Active Biotech AB

Ownership: Private
Employees: ~7
Development stage: Phase 2

Overview

Active Biotech AB is a Swedish clinical-stage biotech company focused on developing drugs to treat cancer, inflammatory eye disease, and neurodegenerative diseases. Its lead programs are in early-to-mid clinical stages. Tasquinimod and naptumomab are both in Phase Ib/II trials; laquinimod has completed a phase I trial. The company’s portfolio includes small molecule immunomodulators and antibody-based therapies. No products have reached late-stage or commercial approval as of May 2025.[1][2][3]

Therapeutic areas: OphthalmologyOncologyNeurology
Modalities: Small molecules (immunomodulators)Antibody-based immunotherapy[1][2]
Industry: Biotech

Drug pipeline

5 assets

laquinimod

4 more assets in the full pipeline.

Request access →

Partnerships

NeoTX Therapeutics Ltd.Perelman School of Medicine at the University of Pennsylvania[1]

Beyond the preview

Go deeper on Active Biotech AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Active Biotech AB.

Explore the full profile